Capstone Holding Corp.
CAPS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.10 Million |
|---|---|
| Enterprise Value | $18.80 Million |
| Earnings per Share | $-123.6 |
| Beta | -1.5 |
| Outstanding Shares | 421,446 |
Return
| Return on Equity | -183.59% |
|---|---|
| Return on Assets | -41.70% |
| Return on Invested Capital | -37.04% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.09 |
| Enterprise Value to Revenue | 0.31 |
| Enterprise Value to EBIT | -1.84 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.12
Consensus analyst estimateRevenue Estimate
$20.39 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$5.70
Consensus analyst estimateRevenue Estimate
$24.60 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Capstone Holding Corp.
36 employees
CEO: Matthew E. Lipman
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its a...